Advances in the treatment of inflammatory arthritis have made a dramatic difference in the lives of people with this disease. However, there is still much to be done. In the Inflammatory Arthritis Center (IAC), our goals are to expand the understanding of how and why inflammatory arthritis develops and to improve patient care. Below are some of our ongoing research projects.
The Accelerating Medicines Partnership (AMP) is a multiyear NIH funded translational research project across numerous sites in the United States. At HSS, Vivian Bykerk, MD, is principal investigator (PI) with co-PIs Lionel Ivashkiv, MD, and Alessandra Pernis, MD. AMP’s primary research focus is to facilitate understanding of RA pathogenesis in differing patient subsets in order to advance aims of precision medicine. Dr. Bykerk and Laura Donlin, PhD, have developed a research program to recruit people living with RA. These patients with joint inflammation volunteer to provide their joint tissue, either at the time of surgery or via a needle biopsy along with information about their health, disease status and treatment. Their collected data will facilitate scientific studies that can discover new mechanisms in the immune system that contribute to the disease and could be targeted for treatment.
The release of the new data for public use in early 2018 speaks to the effectiveness of the AMP RA consortium, a group of engaged researchers across the USA, to provide information that will allow even more scientists to study how the immune system works in rheumatoid arthritis.
To be eligible for all IAC studies (except StopRA), one must be under the care of an HSS rheumatologist.